- Motley Fool•10 hours ago
Carl Icahn has reportedly bought shares in this big-cap biopharma, but Bristol-Myers Squibb might be too big and costly to win an acquirer.
- Zacks•12 hours ago
Pfizer Inc. (PFE) announced that its Biologics License Application (BLA) for leukemia candidate inotuzumab ozogamicin has been accepted for priority review by the FDA.
- Insider Monkey•12 hours ago
Investment Thesis Pfizer Inc. (NYSE:PFE) is one of the world’s largest pharmaceutical firms with sales exceeding $50 billion. The company is currently attractively valued at a blended P/E ratio of 13.3, offering a current dividend yield of 4%. Pfizer is awarded an S&P credit rating of AA and possesses a modest debt to capital ratio […]
PFE : Summary for Pfizer, Inc. Common Stock - Yahoo Finance
Pfizer Inc. (PFE)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||33.25 - 33.75|
|52 Week Range||28.74 - 37.39|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||28.64|
|Dividend & Yield||1.28 (3.81%)|
|1y Target Est||N/A|